| All patients | Patients receiving ADT therapy | Patients not receiving ADT therapy |
Statins users | 7.0 ± 4.8 (N = 146) | 9.6 ± 6.9 (N = 48) | 6.2 ± 3.5 (N = 98) |
Statins non-users | 10.1 ± 9 (N = 255) | 13.8 ± 11.9 (N = 101) | 7.5 ± 4.2 (N = 154) |
Metformin users | 5.4 ± 2.1 (N = 27) | 6.2 ± 1.4 (N=9) | 5.1 ± 2.3 (N = 18) |
Metformin non-users | 9.2 ± 7.9 (N = 373) | 12.7 ± 10.9 (N = 140) | 7.2 ± 4.1 (N = 233) |
Metformin non-users who have diabetes | 13.6 ± 15.3 (N = 21) | 22.7 ± 19.8 (N = 8) | 7.8 ± 8.8 (N = 13) |
Metformin and Statin users | 5.3 ± 1.6 (N = 12) | 7.3 ± undef (N = 1) | 5.2 ± 1.5 (N = 11) |
Alpha-blockers users | 7.5 ± 4.7 (N = 98) | 8.2 ± 4.7 (N = 38) | 7.0 ± 4.7 (N = 60) |
Alpha-blockers non-users | 9.5 ± 8.4 (N = 302) | 13.8 ± 11.8 (N = 111) | 7.0 ± 3.9 (N = 191) |